Equities research analysts expect that Translate Bio Inc (NASDAQ:TBIO) will post ($0.41) earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have issued estimates for Translate Bio’s earnings. The lowest EPS estimate is ($0.57) and the highest is ($0.33). Translate Bio reported earnings per share of ($0.57) in the same quarter last year, which would suggest a positive year over year growth rate of 28.1%. The company is scheduled to announce its next earnings report on Wednesday, July 29th.
On average, analysts expect that Translate Bio will report full-year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.24). For the next financial year, analysts expect that the business will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.63) to ($1.19). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Translate Bio.
Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.20. Translate Bio had a negative return on equity of 63.61% and a negative net margin of 859.22%. The company had revenue of $4.65 million during the quarter, compared to the consensus estimate of $2.23 million.
In other news, major shareholder Baupost Group Llc/Ma purchased 500,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were acquired at an average price of $22.00 per share, with a total value of $11,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Human Genetic Therapies Shire sold 108,472 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $19.86, for a total value of $2,154,253.92. The disclosure for this sale can be found here. Insiders have sold a total of 6,973,550 shares of company stock worth $144,086,787 in the last three months. Corporate insiders own 12.30% of the company’s stock.
Several large investors have recently made changes to their positions in TBIO. HighTower Advisors LLC purchased a new stake in Translate Bio in the 1st quarter valued at approximately $133,000. Wells Fargo & Company MN lifted its stake in Translate Bio by 35.8% in the 1st quarter. Wells Fargo & Company MN now owns 21,446 shares of the company’s stock valued at $214,000 after buying an additional 5,656 shares in the last quarter. Aperio Group LLC purchased a new stake in Translate Bio in the 1st quarter valued at approximately $101,000. Nuveen Asset Management LLC lifted its stake in Translate Bio by 17.7% in the 1st quarter. Nuveen Asset Management LLC now owns 138,522 shares of the company’s stock valued at $1,381,000 after buying an additional 20,855 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in Translate Bio in the 1st quarter valued at approximately $509,000. 83.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of Translate Bio stock traded down $0.44 on Friday, hitting $15.19. The stock had a trading volume of 1,551,167 shares, compared to its average volume of 1,797,509. Translate Bio has a 52-week low of $6.80 and a 52-week high of $28.09. The company has a current ratio of 4.12, a quick ratio of 4.12 and a debt-to-equity ratio of 0.08. The stock has a market cap of $955.59 million, a price-to-earnings ratio of -8.94 and a beta of 0.52. The company’s 50 day moving average price is $18.02 and its 200 day moving average price is $12.76.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Read More: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.